AMED Stock Recent News
AMED LATEST HEADLINES
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock?
Amedisys (AMED) tops on revenue and earnings estimates in the first quarter of fiscal 2024.
The headline numbers for Amedisys (AMED) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amedisys (AMED) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1 per share a year ago.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock?
Amedisys (AMED) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Amedisys said on Tuesday Oregon's health authority has started a review of UnitedHealth Group's $3.3 billion acquisition of the home health and hospice caregiver.
While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.